RZLT vs. AUPH, SNDX, COLL, ELVN, SYRE, BCYC, NTLA, RCKT, ZYME, and ADPT
Should you be buying Rezolute stock or one of its competitors? The main competitors of Rezolute include Aurinia Pharmaceuticals (AUPH), Syndax Pharmaceuticals (SNDX), Collegium Pharmaceutical (COLL), Enliven Therapeutics (ELVN), Spyre Therapeutics (SYRE), Bicycle Therapeutics (BCYC), Intellia Therapeutics (NTLA), Rocket Pharmaceuticals (RCKT), Zymeworks (ZYME), and Adaptive Biotechnologies (ADPT). These companies are all part of the "pharmaceutical products" industry.
Rezolute vs.
Rezolute (NASDAQ:RZLT) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, community ranking, dividends, risk and profitability.
Aurinia Pharmaceuticals received 506 more outperform votes than Rezolute when rated by MarketBeat users. However, 78.82% of users gave Rezolute an outperform vote while only 73.27% of users gave Aurinia Pharmaceuticals an outperform vote.
In the previous week, Rezolute had 2 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 3 mentions for Rezolute and 1 mentions for Aurinia Pharmaceuticals. Rezolute's average media sentiment score of 0.62 beat Aurinia Pharmaceuticals' score of 0.46 indicating that Rezolute is being referred to more favorably in the media.
Rezolute has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.
Rezolute has higher earnings, but lower revenue than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.
Rezolute has a net margin of 0.00% compared to Aurinia Pharmaceuticals' net margin of -10.23%. Aurinia Pharmaceuticals' return on equity of -4.41% beat Rezolute's return on equity.
Rezolute presently has a consensus target price of $24.13, suggesting a potential upside of 404.18%. Aurinia Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 26.98%. Given Rezolute's stronger consensus rating and higher probable upside, equities research analysts clearly believe Rezolute is more favorable than Aurinia Pharmaceuticals.
83.0% of Rezolute shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 18.4% of Rezolute shares are owned by insiders. Comparatively, 4.3% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Rezolute beats Aurinia Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Rezolute News Delivered to You Automatically
Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rezolute Competitors List
Related Companies and Tools
This page (NASDAQ:RZLT) was last updated on 1/21/2025 by MarketBeat.com Staff
Free RZLT Stock Alerts